Article · 5 Oct 2026
Conference abstract
Anticancer noscapinoids: Synthesis to nanomedicine
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Most of the currently available anticancer drugs exert variety of side effects, pose resistance and thereby limit their clinical usefulness. Our group is therefore, actively engaged in design and development of plant derived chemotherapeutic drugs with limited toxicity and lack of drug resistance. Noscapine, a naturally occurring phthalideisoquinoline alkaloid obtained from opium, is a potent cough suppressant being used by the society from long decades. We reported that noscapine causes cell cycle arrest in G2/M phase and promote tumor regression in prostate, breast, brain and lung cancer. Our findings further support that analogues of noscapine synthesized in our laboratory like 9-bromonoscapine, reduced bromonoscapine and 9-aminonoscapine were also 5 to 40~fold more active than parent compound, noscapine. However, physicochemical and biopharmaceutical limitations of noscapine such as short plasma half-life and high ED50~300-500 mg/kg body weight pose obstacles in fabrication of commercially active formulations for the better management of cancer. Therefore, we developed soluble inclusion complex of noscapine with β-CD (β-Cyclodextrin) and enhanced solubility up to 10~fold and oral bioavailability up to 2~fold. The plasma half-life was improved by customizing long circulating stealth gelatin nanoparticles of noscapine. Thus, we presented that noscapinoids will play a pivotal role in the future chemotherapy of cancer
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Bioequivalence & Bioavailability.
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Bioequivalence & Bioavailability
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Ramesh Chandra”
